Glenn Nussdorf Buys 107,494 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf acquired 107,494 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The stock was bought at an average price of $2.99 per share, with a total value of $321,407.06. Following the transaction, the director directly owned 358,495 shares in the company, valued at $1,071,900.05. The trade was a 42.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Organogenesis Stock Down 5.9%

ORGO stock traded down $0.25 during trading on Monday, hitting $4.00. The company had a trading volume of 1,648,527 shares, compared to its average volume of 1,276,991. The firm has a 50-day moving average price of $4.48 and a 200-day moving average price of $4.19. Organogenesis has a 12 month low of $2.61 and a 12 month high of $6.71. The stock has a market cap of $507.43 million, a price-to-earnings ratio of -28.57 and a beta of 1.68.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The company had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. Equities analysts expect that Organogenesis will post -0.07 EPS for the current year.

Institutional Investors Weigh In On Organogenesis

Several institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC bought a new stake in shares of Organogenesis in the 2nd quarter valued at about $24,804,000. Assenagon Asset Management S.A. grew its holdings in Organogenesis by 69.9% during the third quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock worth $20,488,000 after purchasing an additional 1,997,038 shares during the period. Vanguard Group Inc. increased its position in Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after buying an additional 841,618 shares during the last quarter. Acadian Asset Management LLC raised its stake in Organogenesis by 3.9% in the second quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock valued at $8,862,000 after buying an additional 91,118 shares during the period. Finally, Driehaus Capital Management LLC bought a new stake in Organogenesis in the first quarter valued at approximately $7,756,000. 49.57% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ORGO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Organogenesis in a report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of Organogenesis in a report on Friday, September 26th. Finally, Cantor Fitzgerald upped their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Organogenesis presently has a consensus rating of “Hold” and a consensus price target of $7.33.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.